Showing results (31-40 of 68) with videos related to
Sort By:
Pageof 7
Oncology Letters|March 20, 2023
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary studyMichio Kimura, Makiko Go, Shiori Yamada, et al.Journal of Pharmacy Practice|April 23, 2024
Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast CancerMakiko Go, Michio Kimura, Shiori Yamada, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 22, 2024
[Investigation of Factors Related to Overall Survival in Patients Treated with Gemcitabine plus Paclitaxel(Albumin Suspension)for Advanced or Recurrent Pancreatic Cancer]Daisuke Ito, Shoya Takenaka, Akihiro Moriya, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 23, 2016
Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agentsMichio Kimura, Makiko Go, Mina Iwai, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|July 2, 2025
[Impact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study]Koki Mori, Kengo Ohashi, Michio Kimura, et al.Cancer Diagnosis & Prognosis|March 4, 2024
Evaluation of Atezolizumab Plus Bevacizumab <i>Versus</i> Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular CarcinomaMichio Kimura, Shiori Yamada, Makiko Go, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 23, 2024
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinomaMichio Kimura, Shiori Yamada, Makiko Go, et al.Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 2, 2025
[Evaluation of Ixazomib Relative Dose Intensity for IRd Therapy in Elderly Patients with Relapsed or Refractory Multiple Myeloma: A Preliminary Study]Tomoe Kanda, Michio Kimura, Tomoki Sugiyama, et al.Molecular and Clinical Oncology|September 3, 2016
Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancerMakiko Ikagawa, Michio Kimura, Mina Iwai, et al.Oncology Letters|May 29, 2024
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatmentMichio Kimura, Shiori Yamada, Makiko Go, et al.Pageof 7